FibroGen Inc
FGEN
ISIN null / Valor 25953994
FibroGen Inc
UMushroom community rating:
About company
FibroGen Inc is a biopharmaceutical company focused on developing innovative therapies for various medical conditions. One of their potential first-in-class products is FG-3246, an antibody-drug conjugate being developed for metastatic castration-resistant prostate cancer and other tumor types. Another promising drug in their pipeline is Pamrevlumab, a human monoclonal antibody designed to inhibit the activity of connective tissue growth factor in proliferative disorders and certain cancer cell types. Additionally, FibroGen is working on Roxadustat, an oral small molecule inhibitor for treating chemotherapy-induced anemia. These investigational drugs are at various stages of clinical development and have the potential to address significant unmet medical needs in the market.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (14.10.2025):
FibroGen Inc. has announced its financial results for the second quarter of 2025, demonstrating improved revenue and a substantial decrease in net loss compared to the same period in the previous year. The company also highlighted strategic moves, including the sale of FibroGen China, which are expected to extend its financial runway into 2028.
Revenue Growth
Total revenue from continuing operations increased to $1.3 million in Q2 2025, up from $1.0 million in Q2 2024.
Reduced Net Loss
The net loss for continuing operations significantly decreased to $13.7 million, or $3.38 per basic and diluted share, compared to a net loss of $47.1 million, or $11.79 per basic and diluted share, in the second quarter of 2024.
Strengthened Cash Position
As of June 30, 2025, FibroGen reported $23.5 million in cash, cash equivalents, and accounts receivable in the U.S., with a total of $142.1 million consolidated. The anticipated sale of FibroGen China is expected to further extend the company's cash runway into 2028.
Strategic Developments
The company expects the sale of FibroGen China to AstraZeneca to close in the third quarter of 2025 for approximately $210 million. Additionally, FibroGen plans to repay its term loan to Morgan Stanley Tactical Value, simplifying its capital structure.
Future Outlook
FibroGen is advancing its clinical pipeline with upcoming trials for FG-3246 and roxadustat, positioning the company for continued growth and value creation for shareholders and patients.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
35 M
Market cap (USD)
26,571
Daily traded volume (Shares)
0.59 / 0.5133
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
